Wild run aujourd’hui!
J’ai vendu 75% de ma position à 10$ ce matin à 10:00 et le reste a 19$ ce midi ! Avoir sur 
1 « J'aime »
All time high s’en vient. Méchante grosse ride qui fait juste commencer. 120M de volume sur le Nasdaq soit 6x le float.
1 « J'aime »
Tu penses que ça va ouvrir en montant encore ? Quelle serait la raison ? Une bulle ? Spéculation qu’ils vont vendre le brevet des milliards ?
1 « J'aime »
Finalement un bon move, vendu à 19$ et buy back now at 11$. Let see!
2 « J'aime »
Pris sur un autre forum :
Si je ne me trompe pas, c’est illégal aux USA de shorter un stock pour ensuite couvrir la position dans un bought deal mais c’est légal au Canada.
Maintenant que IPA trade sur le Nasdaq et sur le TSXV…est-ce qu’on pourrait quand même voir un bought deal pour couvrir la position short (ou ce qui en reste)? Ça me semble assez massif comme short que soit la majorité a été couvert la journée même ou soit il y a un bought deal sur la table…sinon ça poserait un bon risque de short squeeze non?
Je réfléchis à voix haute. J’essaie de comprendre ce qui s’est passé jeudi.
Peux tu expliquer ce que veux dire ces chiffres?
Est ce le nombre de shares shorts open ou expired a la date indiquee?
MErci!
Ce serait le nombre d’actions vendues qui était short durant chaque jour.
Je n’ai pas la source et le nombre d’actions transigées le 22 juillet était plus élevé alors à prendre avec un grain de sel. J’essaie de comprendre moi aussi ce qui s’est passé derrière les rideaux.
Ils ont couvert le 23 juillet non?
Un bought deal ne peut se faire en 1 jour sans PR.
Possible, je ne sais pas comment voir les positions short en «temps réel» honnêtement, je posais la question si certains savent.
Je sais qu’un bought deal ne se signe pas si rapidement mais c’était en lien avec cet article. Comment ces hedge funds procédaient? Le bought deal devait être «prémédité»?
How short sellers went after this one, bloodied cannabis stock
PS : je précise que je ne fais aucun lien ou présomption ici, j’essaie de comprendre la journée du 22 juillet et comprendre ce qui a pu se passer et de quelle façon différents acteurs du marché auraient pu en profiter
Si toute la position short s’est fait couvrir la journée même, c’est quand même un énorme volume d’acheteur pour une compagnie comme IPA non?
Est ce possible de connaître le volume de short en temps réel? Si oui, ou se trouve l’information?
2 « J'aime »
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021
- Total revenue of $17.9 million, up 27% from $14.1 million in fiscal 2020
- Successfully dual listed to Nasdaq Global Market, subsequently raised USD$25 million in bought deal offering
- Advanced proof-of-concept for TATX-03 COVID-19 program lead asset, effectively neutralizing SARS-CoV-2 Delta variant in non-clinical in vitro study
July 28, 2021 08:02 AM Eastern Daylight Time
VICTORIA, British Columbia–(BUSINESS WIRE)–IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the full fiscal year 2021 ended April 30, 2021.
Fiscal 2021 Financial Summary*
- Earned revenues of $17.9 million, a 27% increase which includes a sale through Talem of an internally generated therapeutic antibody for $1.2 million, core CRO business up 19%
- Research and development costs increased to $2.0 million from $446,280 in 2020 due to the extensive research work the Company is undertaking, including COVID-19 related research projects
- The Company recorded a net loss of $7.3 million during the year ended April 30, 2021, compared to $5.0 million in 2020
- Adjusted EBITDA** of $2.3 million as compared to $52,000 in 2020
- As of April 30, 2021, the Company held cash of $41.8 million
*Expressed in Canadian dollars unless otherwise noted.
**For additional information regarding Adjusted EBITDA (a non-IFRS measure) see the Forward Looking Information section below.
Dr. Jennifer Bath, CEO of ImmunoPrecise, stated, “We are pleased with our solid fiscal year end results, with consistently strong and growing recurring revenue. Looking ahead, we will continue to transform IPA, both strategically and operationally. We continue to execute on strategy including ongoing technology innovation and accelerated discovery of internal and partnered novel antibodies. We also continue to work towards becoming a leading CRO of choice and industry consolidator in the antibody discovery and development markets. As it stands, we have partnered with over 500 clients resulting in very strong recurring revenues following client onboarding for services.”
“As we begin the new fiscal year, we actively seek expansion of our global footprint and push to broaden our diverse portfolio of technologies, while moving pipeline programs further toward functional and pre-clinical development. While in vitro non-clinical evaluation of four programs is currently ongoing, an additional set of five programs in development by Talem Therapeutics are at the stage of final in vitro (functional) characterization and are anticipated to enter in vivo proof of concept studies later this year. Each of these advanced assets are wholly owned by ImmunoPrecise and we look forward to completing functional and in vivo analyses with the aim of maximizing their value prior to any potential out-licensing events,” concluded Dr. Bath.
Recent and Fiscal 2021 Operational Highlights
- Successfully demonstrated pre-clinical in vivo results for TATX-03 PolyTope™ Therapy, a multi-membered monoclonal antibody cocktail designed to retain efficacy against SARS-CoV-2 variants. Results demonstrated strong efficacy for prophylactic and therapeutic use in a well-established SARS-CoV-2 animal model
- Pre-released publication in Biorxiv outlining IPA’s approach to the design and development of TATX-03, also demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) variant
- New co-marketing partnership wherein Eurofins Discovery and ImmunoPrecise co-market non-overlapping service offerings to Eurofins’ global clients, providing greater access to IPA’s end-to-end antibody discovery capabilities
- Presented data on TATX-21, investigational antibodies aimed to prevent low density lipid (LDL) uptake with the goal of preventing and treating Atherosclerosis Cardiovascular Disease (ACVD)
- Added Dr. Ilse Roodink to the role of Chief Scientific Officer and Dr. Dion Neame to Strategic Advisory Board
- Identified a unique antibody with in vivo efficacy in animal model, utilizing an alternative mechanism of action, and which binds all tested SARS-CoV-2 variants of concern
- Successfully launched TATX-112 candidate antibody program, for the treatment of cancer and Alzheimer’s disease
- Established separate development partnerships with Genmab and LiteVax
- Announced the comprehensive screening of twenty-seven proprietary therapeutic antibodies against SARS-CoV-2, identifying antibodies that retained binding to emerging variants of concern including U.K. (B1.1.7 lineage), S. African (B.1.351 lineage) and Brazilian (P.1 lineage) strains
- Solidified research partnership with Mila, a world-renowned research institute dedicated to artificial intelligence (AI) development and focused on deep learning optimization for AI and machine language learning
- Successfully dual listed to NASDAQ global markets stock exchange
- IPA Europe significantly expanded capabilities, releasing its second-generation B cell Select™
- Entered separate collaborations with Twist Bioscience and Zymeworks
Financial Results
Revenue
The Company achieved revenues of $17.9 million during the year ended April 30, 2021, consisting of an increase in its core CRO business of $2.7 million (19%) and a sale through Talem of an internally generated therapeutic antibody for $1.2 million. This represents a 27% increase over 2020 revenues of $14.1 million. The continued growth trend in CRO revenue is due to increases in both volume and financial values of client contracts due to a continued focus on expanding the breadth and depth of service offerings available in-house, new client onboarding and the sustained growth of its core existing business.
Gross Profit
During the year ended April 30, 2021, gross profit was $11.5 million (64% gross profit margin) compared to gross profit of $8.0 million (57% gross profit margin) in 2020. The increase in gross profit is, in part, a result of the sale of an internally generated asset that was expensed as research and development in prior years. Excluding the internally generated asset sale gross profit margin would have been 62%.
Research & Development
Research and development increased to $2.0 million from $446,280 in 2020, due to the extensive R&D work the Company is undertaking, including COVID-19 related research projects.
Other Income (Expenses)
The Company recorded other income of $1.6 million during the year ended April 30, 2021, compared to other expense of ($739,756) in 2020. The increase is primarily related to 2020 government grant income of $1.9 million and subsidies of $844,417 related to COVID-19, a $553,836 reduction in accretion expense related to its obligations, offset by $1.1 million unrealized foreign exchange losses on cash held in US dollars.
Net Loss
The Company recorded a net loss of $7.3 million during the year ended April 30, 2021, compared to net loss of $5 million for the year ended April 30, 2020. The Company achieved higher gross profits and received grant and subsidy income while investing in research and development, and incurring higher share-based payments, salaries, and Nasdaq uplist related costs.
Non-IFRS Measures*
Adjusted EBITDA for the year ended April 30, 2021, was $2.3 million compared to $52,311 for the same period last year. Adjusted EBITDA is management’s view of operating earnings. The significant improvement in Adjusted EBITDA is primarily the result of increased gross profits and awards of government research grants and subsidies related to COVID-19 partially offset by higher research costs, salaries, and expenses related to the Nasdaq uplist.
Cash Position
As of April 30, 2021, the Company held cash of $41.8 million as compared to $2.7 million as of April 30, 2020 and had working capital of $42.8 million. The increase in cash is primarily due to the public offering of the Company’s stock and proceeds from the exercise of warrants and stock options. The Company’s internal forecast indicates the cash on hand will sustain its existing operations, support its Nasdaq and TSXV on-going listing costs and satisfy its obligations through at least fiscal year ending 2023.
Conference Call and Webcast Details
Date: Wednesday, July 28, 2021
Time: 4:30 p.m. Eastern time
Toll-free dial-in number: 1-877-407-3982
International dial-in number: 1-201-493-6780
Conference ID: 13721505
Webcast: Fiscal Year 2021 Earnings Call Link
The conference call will be webcast live and available for replay via the same link found on the main page of the Company’s Investors section at: https://www.immunoprecise.com/investors.
If you are dialing into the call, please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.
Anyone listening to the call is encouraged to read the company’s periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
1 « J'aime »
Well. Mix feeling maintenant. Un beau pump finalement
Bon trimestre (record btw)
Timeline de polytope en ligne avec timeline lors du dernier webinar.
Clairement semble qu’il y a de la manipulation en cours.
Projets Bcell select en hausse, note que c’est projets sont généralement + haut $ # et + haute marge donc je m’attends à une continuité de croissance des rev de la CRO
Le projet au Quebec semble être le genre de projet qui pourrait attirer une subvention.
5 programmes en pre clinique avant la fin de 2021
2 « J'aime »
Dr. Barry Duplantis, Ph.D., promoted to VP of Client Relations Carla Dahl, appointed to VP of Marketing
August 04, 2021 08:02 AM Eastern Daylight Time
VICTORIA, British Columbia–(BUSINESS WIRE)–IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announces the promotion of Dr. Barry Duplantis, Ph.D., to VP of Client Relations and welcomes Ms. Carla Dahl as VP of Marketing.
“Dahl and Duplantis are outstanding additions to IPA’s executive team, each bringing a deep, working knowledge of what it takes to deliver client success”
Dr. Duplantis, who joined the Company in 2018, was previously ImmunoPrecise’s Director of Client Relations, where he was responsible for client interactions and the design and oversight of global therapeutic antibody campaigns. Dr. Duplantis will be responsible for identifying, training, and leading the client relations team while ensuring execution of ImmunoPrecise’s full sales lifecycle from targeting to closing of new business.
Prior to ImmunoPrecise, Dr. Duplantis, who possesses over a decade of industry experience, was founder and CEO of DuVax Vaccines and Reagents, where he developed and implemented a patented platform technology to genetically engineer bacterial species, aiding in the creation of live-attenuated vaccines from benchtop to in vivo preclinical studies. During this time, he formed partnerships with major pharmaceutical companies and was awarded multiple translational science grants, amongst other accolades. Dr. Duplantis has a Ph.D. in Biochemistry and Microbiology and a BSc in Chemistry and Biochemistry from the University of Victoria.
“I was very excited to join the ImmunoPrecise team in 2018 and continue to be so,” stated Dr. Duplantis. “I am extremely appreciative for this new opportunity and am looking forward to applying my unique skill set to help drive the growth of this highly innovative company.”
Ms. Carla Dahl, who has over 25 years of experience in leadership and entrepreneurial roles across consumer health, life sciences marketing communications and branding joins ImmunoPrecise as VP of Marketing, where she will lead IPA’s brand amplification initiatives including industry awareness of IPA’s products and services as well as highly targeted marketing and communications campaigns directly aimed at driving revenue.
Prior to joining ImmunoPrecise, Ms. Dahl was Sr. Director Marketing Communications and Marketing Operations for Medtronic in Plymouth, MN, where she was brought in to optimize the marketing and communications functions of the CVG/APV division of the organization. Ms. Dahl also held senior marketing and communications roles with Preceptis Medical and St. Jude Medical. Prior to this, Ms. Dahl was the founder of Parentprops where she designed, owned, and patented an initial and subsequent full line of upscale retail/consumer products for distribution nationwide which were sold and distributed nationwide by Target Corp. Ms. Dahl holds a BA in English and a minor in Philosophy from the University of Minnesota.
“I am honored to join the IPA team and help to build on the solid foundation developed over the past several years. ImmunoPrecise is well positioned to transform and elevate how pharmaceutical companies perceive outsourcing of therapeutic antibody discovery and development, and I look forward to helping craft and share that story with stakeholders and clients alike,” stated Ms. Carla Dahl.
Dr. Jennifer Bath, President and CEO of ImmunoPrecise, commenting on the appointments, noted “Dahl and Duplantis are outstanding additions to IPA’s executive team, each bringing a deep, working knowledge of what it takes to deliver client success,” said Dr. Jennifer Bath, President and CEO of ImmunoPrecise. “As IPA continues its rapid growth and focuses across the N. America, Asia and Europe, their sales and marketing leadership and strong backgrounds in building top performing teams will accelerate IPA’s growth. Human capital has always been at the core of IPA’s foundational principles, and we are very excited over these recent additions. We believe that their contributions will deeply impact both our brand and reputation further with new and existing customers alike.”
Coronavirus cases and hospitalizations in the United States are at a six-month high, fueled by the rapid spread of the Delta variant across swathes of the country grappling with low vaccination rates.
Nationwide, COVID-19 cases have averaged 100,000 for three days in a row, up 35% over the past week, according to a Reuters tally of public health data. Louisiana, Florida and Arkansas reported the most new cases in the past week, based on population. (Graphic of U.S. coronavirus cases)
Hospitalizations rose 40% and deaths, a lagging indicator, registered an 18% uptick in the past week with the most fatalities by population in Arkansas.
une autre acquisition:
Pfizer to Acquire Trillium Therapeutics Inc.
Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies
Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond
Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives
NEW YORK and CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) – Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash. This represents a 118% premium to the 60-day weighted average price for Trillium.
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells. Its two lead molecules, TTI-622 and TTI-621, block the signal-regulatory protein α (SIRPα)–CD47 axis, which is emerging as a key immune checkpoint in hematological malignancies. TTI-622 and TTI-621 are novel, potentially best-in-class SIRPα-Fc fusion proteins that are currently in Phase 1b/2 development across several indications, with a focus on hematological malignancies.
2 « J'aime »
Intéressant de voir qu’IPA embauche à Toronto. À ma connaissance, IPA n’a pas de place d’affaires à Toronto.
Est-il possible qu’il y ait un lien avec l’annonce de Sanofi du 31 mars 2021 ?
Sanofi to build new manufacturing facility in Toronto to strengthen domestic pandemic preparedness and increase global supply of high-dose influenza vaccine
IPA a également nommé Dr. Dion Neame au Conseil Consultatif Stratégique le 25 mai 2021. Dr. Dion Neame is the Country Medical Lead for Sanofi Canada and Country Medical Head for Pasteur, the vaccine arm of Sanofi"
4 « J'aime »